It has been revealed in the study that after 10 weeks the level of antibodies can be reduced by more than 50 percent. This study was done on 600 people aged 18 years and above. This included women and men, including those with chronic illness. In India, the AstraZeneca vaccine is being made at the Serum Institute of India under the name Covishield.
Researchers from University College London (UCL) say that this rapid decline in antibodies is a matter of concern. There is also a possibility of the vaccine losing its effect. This concern can be high especially against the new variants.
It has also been found in the study that after taking 2 doses of AstraZeneca, taking 2 doses of Pfizer vaccine, the level of antibodies remains very good. Apart from this, the level of antibodies has been found higher in those who got Kovid vaccination compared to people who had Kovid infection.
Madhumita Shrotri of the UCL Institute of Health Informatics says, “After both doses of the AstraZeneca or Pfizer vaccine, the antibody levels are initially very high, which gives a person strong protection against severe COVID-19. However, in the study, we found that there has been a significant decline in its level over the course of two to three months.
Give booster dose to the elderly first
Regarding the booster dose, Professor Rob Aldridge of the UCL Institute of Health Informatics said, ‘If it is thought about which people should be given priority in terms of giving booster doses, then according to our data, those taking the AstraZeneca vaccine should be selected. . These people are likely to have the lowest levels of antibodies. Apart from this, booster doses should be given to people aged 70 years or more on priority basis.
However, the team involved in the study has admitted that they have done this study on very few people. Apart from this, the people on whom this study has been done, they have given only one sample of their own, so it is difficult to tell how quickly the antibody level falls or it remains stable for the next few months. At the same time, he also said that it will be important to do further research to know whether there is a limit of antibody level to prevent serious disease. (with agency input)